Barclays’s Ironwood Pharmaceuticals IRWD Stock Holding History

Barclays’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-348,000	Closed	-$3.03M	–	5084
2024 Q1	$3.03M	Hold	348,000	–	–	﹤0.01%	2222
2023 Q4	$3.98M	Buy	348,000 +201,400	+137%	+$1.99M	﹤0.01%	2307
2023 Q3	$1.41M	Buy	+146,600	New	+$1.44M	﹤0.01%	2112
2019 Q1	–	Sell	-59,700	Closed	-$518K	–	7160
2018 Q4	$518K	Sell	59,700 -1,194	-2%	-$13.7K	﹤0.01%	3791
2018 Q3	$941K	Buy	60,894 +59,700	+5,000%	+$944K	﹤0.01%	3686
2018 Q2	$19K	Buy	+1,194	New	+$17.7K	﹤0.01%	6215
2018 Q1	–	Sell	-477,600	Closed	-$6M	–	7187
2017 Q4	$6M	Buy	+477,600	New	+$6.24M	﹤0.01%	1524
2016 Q2	–	Sell	-119,400	Closed	-$1M	–	6462
2016 Q1	$1M	Buy	+119,400	New	+$985K	﹤0.01%	2522
2014 Q3	–	Sell	-223,875	Closed	-$2.81M	–	7733
2014 Q2	$2.81M	Buy	+223,875	New	+$2.43M	﹤0.01%	2271

Other funds holding IRWD

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Barclays's IRWD Position: Q1 2026 in Review

Barclays reduced its Ironwood Pharmaceuticals (IRWD) stake by 77% in Q1 2026, selling an estimated $1.24M and leaving 89,970 shares worth $316K. The position accounts for ﹤0.01% of the portfolio, ranked #3450.

Barclays first reported a position in IRWD in Q2 2013 and has held it in 52 quarters since. The position peaked at $6.32M in Q4 2023. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

Barclays held 89,970 shares of Ironwood Pharmaceuticals worth $316K as of Q1 2026.
Barclays sold 302,934 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $1.24M.
Ironwood Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3450 holding.
Barclays first reported a position in Ironwood Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Barclays's Ironwood Pharmaceuticals position peaked at $6.32M in Q4 2023.
226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.